Ephrin type-A receptor 3 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Ephrin type-A receptor 3 shows clinical signal disease relevance led by glioblastoma multiforme. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P29320. Start with glioblastoma multiforme, then reuse UniProt P29320 as the stable protein anchor across project notes and exports.
Start with glioblastoma multiforme, then reuse UniProt P29320 as the stable protein anchor across project notes and exports.
Ephrin type-A receptor 3 shows clinical signal disease relevance led by glioblastoma multiforme. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with glioblastoma multiforme because it currently carries clinical signal support. Linked drugs include KB-004. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyEphrin type-A receptor 3
Review this target as Ephrin type-A receptor 3, mapped to UniProt P29320. Sequence length is 983 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Ephrin type-A receptor 3 as ChEMBL target CHEMBL4954, mapped to UniProt P29320. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Ephrin type-A receptor 3 is the right protein anchor across sources, using UniProt P29320 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why glioblastoma multiforme is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Ephrin type-A receptor 3 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P29320 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Ephrin type-A receptor 3 |
| UniProt Accession | P29320 |
| Component Type | Protein |
| Sequence Length | 983 aa |
Ephrin type-A receptor 3
Review this target as Ephrin type-A receptor 3, mapped to UniProt P29320. Sequence length is 983 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Ephrin type-A receptor 3 shows clinical signal disease relevance led by glioblastoma multiforme. 2 more disease programs remain visible in the same review block.
Start review with glioblastoma multiforme because it currently carries clinical signal support. Linked drugs include KB-004. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL5416410 | 10.03 | Kd | 0.093 | Approved |
| CHEMBL249097 | 10.0 | Kd | 0.1 | Preclinical |
| CHEMBL1421 | 9.52 | IC50 | 0.3 | Approved |
| CHEMBL3752910 | 9.52 | IC50 | 0.3 | Preclinical |
| CHEMBL1230609 | 9.0 | Kd | 1.0 | Clinical |
| CHEMBL1784637 | 8.92 | IC50 | 1.2 | Preclinical |
| CHEMBL459850 | 8.7 | EC50 | 2.0 | Preclinical |
| CHEMBL2336005 | 8.29 | IC50 | 5.1 | Preclinical |
| CHEMBL288441 | 8.24 | Kd | 5.8 | Approved |
| CHEMBL386051 | 8.12 | Kd | 7.6 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 200 | 56 | 6.4 |
| assay format | 30 | 5 | 7.4 |
| cell-based format | 16 | 11 | 6.4 |
| cell membrane format | 2 | 1 | 8.3 |